AVT 01

Drug Profile

AVT 01

Alternative Names: AVT-01 decoy ODN; AVT-01 decoy oligodeoxynucleotide; AVT01

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Gottingen
  • Developer DOLTHERA
  • Class Anti-inflammatories; Antiasthmatics; Oligonucleotides
  • Mechanism of Action STAT1 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 22 Jan 2008 AVT 01 is still in phase IIa trials for asthma in the UK and Romania
  • 13 Nov 2006 Phase-II clinical trials in Asthma in Romania (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top